Phase 1 Study of KRN951

An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients with Solid Tumors

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220823

Enrollment

Registered

2009-08-20

Start date

2009-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : KRN951 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Signed written informed consent Solid tumors to be unresponsive to, or untreatable by standard therapies Three-month or more life expectancy Eastern Cooperative Oncology Group Performance Status score of 0, 1 or 2

Exclusion criteria

Exclusion criteria: Hematologic abnormality Myocardial infarction or clinically symptomatic left ventricular failure Active hypertension or controllable hypertension more than 3 antihypertensive medications Symptomatic CNS metastasis Unhealed wounds Active infections Hepatic or renal functional disorder Any of the HBs antigen, HCV antibody and HIV antibody positivity Prior use of any chemotherapy, radiotherapy, immunotherapy or surgery within four weeks previous to first dose of study drug Pregnant or lactating women Women of childbearing potential and fertile men, unless willing to use adequate contraceptive protection

Design outcomes

Primary

Measure	Time frame
To define the maximum tolerated dose (MTD) of KRN951	—

Secondary

Measure	Time frame
Pharmacokinetics and anti-tumor activity	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026